The 18 most recent market catalysts affecting $GILD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
Gilead Sciences Announces Expansion Of Six Royalty-Free Voluntary Licensing Agreements To Cover Once-Yearly Lenacapavir For HIV Prevention Across 120 Countries
Gilead's expansion of royalty-free licensing for Lenacapavir is a significant positive for the company, as it broadens the drug's availability for HIV prevention across 120 countri…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 55
Gilead And PAHO Partner To Expand Twice-Yearly Lenacapavir HIV Prevention Access Across Latin America And The Caribbean
Gilead Sciences has entered into an agreement with the Pan American Health Organization (PAHO) to facilitate broader access to its long-acting HIV prevention drug, lenacapavir, acr…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 65
Gilead Exec Says HIV Market Growth Should Normalize To 2%-3% Within Next Couple Of Quarters
A Gilead Sciences executive, likely during an investor event or conference call referenced by the webcast link, stated that the HIV market growth rate is anticipated to normalize t…
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 65
Gilead Sciences Exec Says Weekly Oral HIV Prevention Drug Expected To Launch In Q1 2027
Gilead Sciences, a major player in HIV treatment and prevention, has provided a specific timeline for the launch of its weekly oral HIV prevention drug: Q1 2027. This announcement,…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175
HSBC's analyst Morten Herholdt maintaining a 'Buy' rating and raising the price target for Gilead Sciences from $155 to $175 indicates increased confidence in the company's financi…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
Gilead Sciences Announces FDA Approval For Bixlenvo, The Smallest Once-Daily Single Tablet Regimen For The Treatment Of HIV In Adults Who Are Virologically Suppressed
Gilead Sciences has secured FDA approval for Bixlenvo, a novel single tablet regimen for HIV. This is significant as Bixlenvo is the smallest once-daily STR and specifically target…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer
Gilead Sciences announced the European Commission's marketing authorization for its Trodelvy-Keytruda combination therapy for first-line metastatic triple-negative breast cancer (T…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123
RBC Capital analyst Brian Abrahams updated his coverage on Gilead Sciences, maintaining a 'Sector Perform' rating but raising the price target from $120 to $123. This adjustment re…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 55
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target
Needham analyst Joseph Stringer reiterated a 'Buy' rating and maintained a $170 price target for Gilead Sciences. This action signals continued confidence from a prominent analyst …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Fully Underway For Anito-Cel Cell Therapy, With Five Months To Go Until FDA PDUFA Date; Do Not Currently Anticipate Pursuing Additional Sizable M&A Transactions This Year
Gilead Sciences announced an upward revision of its full-year HIV growth expectations from 8% to 9%-10% year-over-year. This is a significant positive development for the company, …
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 85
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est
Gilead Sciences has announced a significant reduction in its GAAP EPS guidance for FY2026, moving from a range of $(3.25)-$(2.85) to $(3.75)-$(3.40). This new guidance is considera…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 75
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est
Gilead Sciences (GILD) has raised its FY2026 adjusted EPS guidance from a range of $(1.05)-$(0.65) to $(0.65)-$(0.30), significantly narrowing the loss and improving the outlook co…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 92
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate
Gilead Sciences announced Q2 adjusted EPS of $(6.75), which, while a loss, significantly beat the analyst consensus of $(7.24). This beat, despite being a 435.82% decrease from the…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 75
Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer
Gilead's Trodelvy, in combination with Merck's Keytruda, received a positive opinion from the EMA's CHMP for first-line treatment of PD-L1 positive metastatic triple-negative breas…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 75
Gilead Sciences shares are trading lower after Leerink Partners downgraded its rating on the stock from Outperform to Market Perform and lowered its price target from $146 to $127.
This headline represents a significant corporate catalyst for Gilead Sciences. Analyst downgrades, especially from 'Outperform' to 'Market Perform' with a substantial price target …
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 85
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
Gilead Sciences and Merck & Co. have reported detailed Phase 3 results for their once-weekly oral HIV regimen, ISL/LEN, showing it maintained viral suppression and was non-inferior…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 65
Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127
Leerink Partners' analyst Daina Graybosch downgraded Gilead Sciences (GILD) from an 'Outperform' rating to 'Market Perform' and significantly lowered the price target from $146 to …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.